Genmab — Januar 2018
-
At a JPM presentation on January 10, Editas CEO Katrine Bosley said the company has "successfully tackled all the translation science questions" that come along with clinical development, including immunogenicity- implying that getting ahead of the issues presented by the manuscript is simply a standard part of translational science. Kulkarni had the same sentiment, saying that "in any therapeutic development, you do immunogenicity testing anyway…I think the concerns are overblown."
-
You must have a lot of respect for Dara if you put this in your company update: "I-MAB’s head of R&D was formerly responsible for the clinical development of Daratumumabin China as Janssen China’s head of development" Morphosys p12 https://www.morphosys.de/sites/default/files/presentations/180110_mor_company_udate_talk_jpm_final.pdf
-
Er det senest den 21. FDA skal komme tilbage med priority review eller ej?
-
Det håber vi på. Tak skal du have.
-
Året startede i 1029. Indtil nu op med 10,3% på året. Rigtig god start på året for Genmab
-
Det kan jo også være at Artisan er i gang med at købe flere. De skal jo ikke rapportere før de rammer 10%
-
To dage med beskedent fald og beskedent nettosalg fra A/B.
-
I går øgede købet fra A/B pænt i slutauktionen.
-
Begge dag har der været pæn modstand i 1120´erne.
-
I dette område har eventuelle shortere ikke øget trykket.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind